Improving PrEP protection of transgender women through mechanistic pharmacokinetic understanding

通过机制药代动力学理解改善跨性别女性的 PrEP 保护

基本信息

  • 批准号:
    9891005
  • 负责人:
  • 金额:
    $ 56.76万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-03-11 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The goal of this work is to improve the medical care of transgender women (TGW) through understanding the interaction of drugs for pre-exposure prophylaxis (PrEP) for prevention of HIV acquisition and gender affirming hormonal therapy (GAHT). Professional Societies recommend estrogen-based GAHTs for TGW to promote feminization and demasculinization in order to facilitate gender transition and diminish gender dysphoria. TGW are a vulnerable population, who experience significant challenges, including gender dysphoria, depression, and discrimination, all resulting in a compromised quality of life. There are barriers for transgender persons in terms of employment and healthcare, further preventing members of the community from receiving culturally competent care. In addition, TGW are 49-times at greater risk for HIV acquisition when compared to cisgender men (CGM) and women (CGW) of reproductive age. Currently, a daily, fixed dose formulation of tenofovir (TFV) disoproxil fumarate (TDF)/emtricitabine (FTC) (PrEP), has been used for the prevention of HIV acquisition in persons at high risk of HIV infection. A less-frequent, on demand, four-dose regimen has also proven highly effective in preventing HIV infection. While TGW have been enrolled in randomized controlled PrEP trials, TGW have not been enrolled in sufficient numbers to robustly evaluate PrEP uptake and efficacy. Importantly, the interaction of PrEP and GAHT drugs has not been well characterized. In vitro and ex vivo studies suggest an influence of estrogen and, potentially reduced testosterone, on PrEP pharmacology. Preliminary work by our group demonstrated greater than 30% reduction in plasma TFV and FTC AUC0-24 in TGW on estrogen when compared to CGM. Because reducing the weekly TDF/FTC dose from seven to two doses per week results in a sizeable drop in PrEP protection of anal sex from 90 to 75%, the change we observed may be sufficiently large to impact PrEP outcomes in TGW on GAHT. Thus, to better characterize the relationship between PrEP and GAHT, we propose a clinical drug-drug interaction between PrEP drugs and estrogen-based GAHT in a stepwise and estrogen dose-dependent manner to quantify the magnitude of drug interaction in blood, urine, and colorectal tissue. We will use these data, in conjunction with other clinical trials data, to build a population pharmacokinetic-pharmacodynamic model of PrEP efficacy. This will enable clinical trial simulations to contrast daily and on demand PrEP dosing in the presence and absence of GAHT to inform PrEP dose recommendations for TGW. Because we hypothesize that GAHT will decrease PrEP concentrations and result in increased susceptibility for HIV infection, TGW on GAHT will likely require higher or more frequent PrEP dosing than CGM who have sex with men. This work is a critical next step in ensuring appropriate PrEP dosing to group at substantially higher risk of HIV acquisition, and informs the need and design for future study of PrEP and GAHT from an efficacy, behavioral, and acceptability perspective.
项目摘要 这项工作的目标是通过了解跨性别妇女(TGW)的医疗保健, 暴露前预防药物(PrEP)预防HIV感染和性别确认的相互作用 激素治疗(GAHT)。专业协会建议TGW推广基于雌激素的GAHT 消除女性化和非男性化现象,以促进性别过渡和减少性别焦虑。TGW 是弱势群体,他们面临重大挑战,包括性别焦虑,抑郁症, 和歧视,所有这些都导致生活质量下降。跨性别者在以下方面存在障碍: 就业和医疗条件,进一步阻止社区成员接受文化 称职的照顾。此外,与顺性别者相比,TGW感染艾滋病毒的风险高49倍 男性(CGM)和育龄女性(CGW)。目前,替诺福韦的每日固定剂量制剂 (TFV)富马酸二异山梨酯(TDF)/恩曲他滨(FTC)(PrEP)已用于预防HIV 艾滋病毒感染高危人群中的艾滋病感染。一种频率较低的按需四剂方案也 在预防艾滋病毒感染方面非常有效。虽然TGW已入组随机对照研究, PrEP试验,TGW尚未招募足够数量的患者来稳健地评估PrEP吸收和疗效。 重要的是,PrEP和GAHT药物的相互作用尚未得到很好的表征。体外和离体 研究表明雌激素和潜在减少的睾酮对PrEP药理学的影响。 我们小组的初步工作表明,在2009年, 与CGM相比,TGW对雌激素的影响。因为将每周TDF/FTC剂量从7次减少到2次, 每周剂量导致PrEP对肛交的保护从90%大幅下降至75%, 观察到的可能足够大,以影响GAHT上TGW的PrEP结果。因此,为了更好地表征 PrEP和GAHT之间的关系,我们提出了PrEP药物之间的临床药物相互作用 和基于雌激素的GAHT以逐步和雌激素剂量依赖的方式定量 血液、尿液和结肠直肠组织中的药物相互作用。我们将使用这些数据,结合其他临床 试验数据,以建立PrEP疗效的群体药代动力学-药效学模型。这将使 临床试验模拟,以对比在存在和不存在GAHT的情况下每日和按需PrEP给药, 告知TGW的PrEP剂量建议。因为我们假设GAHT会减少PrEP 浓度,并导致艾滋病毒感染的易感性增加,GAHT上的TGW可能需要更高的 或更频繁的PrEP剂量比CGM谁与男性发生性关系。这项工作是确保 适当的PrEP剂量组在艾滋病毒感染的高风险,并告知需要和 从有效性、行为和可接受性的角度设计未来的PrEP和GAHT研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark A Marzinke其他文献

Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother–infant pairs (MTN-043): a phase 3B, open-label, randomised trial
达匹韦林阴道环和口服暴露前预防在母乳喂养母婴对(MTN-043)中的安全性和药物定量:一项 3B 期、开放标签、随机试验
  • DOI:
    10.1016/s2352-3018(24)00306-0
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    13.000
  • 作者:
    Lisa M Noguchi;Maxensia Owor;Nyaradzo M Mgodi;Brenda Gati Mirembe;Sufia Dadabhai;Elizea Horne;Holly Gundacker;Barbra A Richardson;Katherine Bunge;Rachel Scheckter;Mei Song;Mark A Marzinke;Peter L Anderson;Edward Livant;Cindy Jacobson;Jeanna M Piper;Nahida Chakhtoura;Sharon L Hillier;Jennifer E Balkus;MTN-043 Study Team
  • 通讯作者:
    MTN-043 Study Team
Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study
长效注射用卡博特韦和长效注射用利匹韦林在接受抗病毒治疗且病毒载量得到抑制的青少年艾滋病患者中的安全性(IMPAACT 2017/MOCHA):一项 1/2 期、多中心、开放标签、非对照、剂量探索研究
  • DOI:
    10.1016/s2352-3018(24)00344-8
  • 发表时间:
    2025-03-01
  • 期刊:
  • 影响因子:
    13.000
  • 作者:
    Carolyn Bolton Moore;Kristin Baltrusaitis;Brookie M Best;John H Moye;Ellen Townley;Avy Violari;Barbara Heckman;Sarah Buisson;Rodica M Van Solingen-Ristea;Edmund V Capparelli;Mark A Marzinke;Elizabeth D Lowenthal;Shawn Ward;Chelsea Krotje;Ryan Milligan;Allison L Agwu;Jenny Huang;S Y Amy Cheung;Cynthia McCoig;Dwight E Yin;Jon W. Collins
  • 通讯作者:
    Jon W. Collins
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial
长效卡博特韦与每日口服富马酸替诺福韦二吡呋酯联合恩曲他滨预防与男性发生性关系的顺性别男性和跨性别女性感染艾滋病毒的疗效和安全性:第 2b 阶段和第 3 阶段 HPTN 083 随机对照试验研究揭盲后 1 年的二次分析
  • DOI:
    10.1016/s2352-3018(23)00261-8
  • 发表时间:
    2023-12-01
  • 期刊:
  • 影响因子:
    13.000
  • 作者:
    Raphael J Landovitz;Brett S Hanscom;Meredith E Clement;Ha V Tran;Esper G Kallas;Manya Magnus;Omar Sued;Jorge Sanchez;Hyman Scott;Joe J Eron;Carlos del Rio;Sheldon D Fields;Mark A Marzinke;Susan H Eshleman;Deborah Donnell;Matthew A Spinelli;Ryan M Kofron;Richard Berman;Estelle M Piwowar-Manning;Paul A Richardson;Beatriz Grinsztejn
  • 通讯作者:
    Beatriz Grinsztejn

Mark A Marzinke的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark A Marzinke', 18)}}的其他基金

Improving PrEP protection of transgender women through mechanistic pharmacokinetic understanding
通过机制药代动力学理解改善跨性别女性的 PrEP 保护
  • 批准号:
    10355444
  • 财政年份:
    2019
  • 资助金额:
    $ 56.76万
  • 项目类别:
Bioanalytical and Formulation Core
生物分析和配方核心
  • 批准号:
    8768694
  • 财政年份:
    2014
  • 资助金额:
    $ 56.76万
  • 项目类别:
Bioanalytical and Formulation Core
生物分析和制剂核心
  • 批准号:
    8889594
  • 财政年份:
  • 资助金额:
    $ 56.76万
  • 项目类别:
Bioanalytical and Formulation Core
生物分析和制剂核心
  • 批准号:
    9313777
  • 财政年份:
  • 资助金额:
    $ 56.76万
  • 项目类别:
Bioanalytical and Formulation Core
生物分析和配方核心
  • 批准号:
    9088360
  • 财政年份:
  • 资助金额:
    $ 56.76万
  • 项目类别:

相似海外基金

心房細動に対するPulsed Field Ablationの組織創傷治癒過程を明らかにする網羅的研究
阐明房颤脉冲场消融组织伤口愈合过程的综合研究
  • 批准号:
    24K11201
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
遅延造影心臓MRIによる心房細動Ablation冷却効果の比較:28 vs. 31 mm Cryoballoon
使用延迟对比增强心脏 MRI 比较房颤消融冷却效果:28 毫米与 31 毫米 Cryoballoon
  • 批准号:
    24K11281
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
InSPACE-VT_Development and Validation of Virtual Pace Mapping to Guide Catheter Ablation of Ventricular Tachycardia
InSPACE-VT_虚拟起搏测绘的开发和验证以指导室性心动过速导管消融
  • 批准号:
    EP/Z001145/1
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Fellowship
CAREER: Heat Penetration Depth and Direction Control with Closed-Loop Device for Precision Ablation
职业:利用闭环装置控制热穿透深度和方向,实现精确烧蚀
  • 批准号:
    2338890
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334777
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334775
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Continuing Grant
Collaborative Research: RUI: Frontal Ablation Processes on Lake-terminating Glaciers and their Role in Glacier Change
合作研究:RUI:湖终止冰川的锋面消融过程及其在冰川变化中的作用
  • 批准号:
    2334776
  • 财政年份:
    2024
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Continuing Grant
MRI: Acquisition of a Laser Ablation - Inductively Coupled Plasma - Triple Quadrupole - Mass Spectrometer (LA-ICP-QQQ-MS) System For Research and Education
MRI:获取用于研究和教育的激光烧蚀 - 电感耦合等离子体 - 三重四极杆 - 质谱仪 (LA-ICP-MS/MS) 系统
  • 批准号:
    2320040
  • 财政年份:
    2023
  • 资助金额:
    $ 56.76万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了